Compositions for targeting the vasculature of solid tumors
AssigneeBoard of Regents, The University of Texas System
InventorsPhilip E. Thorpe, Francis J. Burrows
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
Claims61
A compound comprising a targeting agent operatively attached to a therapeutic agent, wherein the targeting agent binds to a tumor-associated endothelial cell marker expressed, accessible to binding or localized on the cell surface of intratumoral blood vessels of a vascularized tumor.
A conjugate comprising an antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the antibody is linked to a therapeutic agent that is capable of exerting a cytotoxic effect on the tumor vasculature.
A compound comprising a targeting agent operatively attached to a therapeutic agent, wherein the targeting agent binds to a tumor-associated endothelial cell marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor.
A conjugate comprising a targeting agent linked to a therapeutic agent, wherein the targeting agent binds to a tumor-associated endothelial cell marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor.
A conjugate comprising an antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the antibody is linked to a therapeutic agent.
A conjugate comprising an antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the antibody is linked to a therapeutic agent that has a cytotoxic effect on the tumor vasculature.
A conjugate comprising an antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the antibody is linked to a therapeutic agent that is capable of exerting a cytotoxic effect on the intratumoral vasculature sufficient to destroy intratumoral blood vessels.
A conjugate comprising an antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the antibody is linked to a therapeutic agent that is capable of exerting a cytotoxic effect on the tumor vasculature sufficient to lead to tumor necrosis.
In combination:
- (a) a first conjugate comprising a first antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the first antibody is linked to a therapeutic agent that is capable of exerting a cytotoxic effect on the tumor vasculature;
- and
- (b) a second conjugate comprising a second antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the second antibody is linked to a diagnostic agent that is detectable upon imaging.
A kit comprising:
- (a) a first conjugate comprising a first antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the first antibody is linked to a therapeutic agent that is capable of exerting a cytotoxic effect on the tumor vasculature;
- and
- (b) a second conjugate comprising a second antibody, or an antigen-binding portion thereof, that binds to a marker expressed or localized on the cell surface of intratumoral blood vessels of a vascularized tumor, wherein the second antibody is linked to a diagnostic agent that is detectable upon imaging.
Dependencies are inferred from the claim text.